Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14, 374
by
, , ,
Simon Bailey
1,2,*,†
,
Nicolas André
3,4,†,
Lorenza Gandola
5,†,
Maura Massimino
6,‡
,
Keith Wheatley
7,
Simon Gates
7,
Victoria Homer
7,
Stefan Rutkowski
8,‡ and
Steven C. Clifford
2,‡ 1
Great North Children’s Hospital, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK
2
Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
3
Pediatric Hematology and Oncology Department, Hôpital Pour Enfants de La Timone, AP-HM, 13005 Marseille, France
4
Centre de Recherche en Cancérologie de Marseille, SMARTc Unit, Inserm U1068, Aix Marseille University, 13005 Marseille, France
5
Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
6
Pediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
7
Cancer Research UK Clinical Trials Unit, University of Birimingham, Birmingham B15 2TT, UK
8
Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
These authors contributed equally to this work.
Cancers 2024, 16(6), 1084; https://doi.org/10.3390/cancers16061084
Submission received: 12 January 2024
/
Accepted: 2 February 2024
/
Published: 7 March 2024
(This article belongs to the Special Issue Medulloblastoma Systemic Therapy Clinical Trials and Their Foundations)
Missing Funding
In the original publication [1], the funder Cancer Research UK, A2524 was not included.
Addition of Authors
Keith Wheatley, Simon Gates, and Victoria Homer were not included as authors in the original publication. The reason we would like to add the authors is that the statistical element of the trial and the trial design were in a large part done by the statistical authors and the team were necessary for the running of the trial. The corrected Author Contributions Statement appears here.
- Author Contributions: Conceptualization, S.B., N.A., L.G., M.M., K.W., S.R. and S.C.C.; methodology, K.W., S.G. and V.H.; project administration, S.G. and V.H.; resources, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—original draft preparation, S.B., N.A., L.G., M.M., S.R. and S.C.C.; writing—review and editing, S.B., N.A., L.G., M.M., S.R. and S.C.C. All authors have read and agreed to the published version of the manuscript.
Additional Affiliation
Cancer Research UK Clinical Trials Unit, University of Birimingham, Birmingham B15 2TT, UK; [email protected](K.W.); [email protected] (S.G.); [email protected] (V.H.)
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Bailey, S.; André, N.; Gandola, L.; Massimino, M.; Rutkowski, S.; Clifford, S.C. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14, 374. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Bailey, S.; André, N.; Gandola, L.; Massimino, M.; Wheatley, K.; Gates, S.; Homer, V.; Rutkowski, S.; Clifford, S.C. Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14, 374. Cancers 2024, 16, 1084. https://doi.org/10.3390/cancers16061084
AMA Style
Bailey S, André N, Gandola L, Massimino M, Wheatley K, Gates S, Homer V, Rutkowski S, Clifford SC. Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14, 374. Cancers. 2024; 16(6):1084. https://doi.org/10.3390/cancers16061084
Chicago/Turabian StyleBailey, Simon, Nicolas André, Lorenza Gandola, Maura Massimino, Keith Wheatley, Simon Gates, Victoria Homer, Stefan Rutkowski, and Steven C. Clifford. 2024. "Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14, 374" Cancers 16, no. 6: 1084. https://doi.org/10.3390/cancers16061084
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
